Targeted therapies in the management of renal cell carcinoma: role of bevacizumab
Bernard Escudier1, Jan Cosaert2, Sangeeta Jethwa21Unité Immunothérapie, Institut Gustave Roussy, Villejuif, France; 2F. Hoffmann-La Roche Ltd, Basel, SwitzerlandAbstract: Bevacizumab (10 mg/kg every 2 weeks), in combination with interferon alpha-2a (IFN), is an effectiv...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Dove Medical Press
2008
|
| Subjects: | |
| Online Access: | https://doaj.org/article/d19bb4fcab0d4f1794b552ac3168d89d |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|